These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34761847)

  • 1. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
    Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN; Dodge JL; Hirose R; Heimbach J; Yao FY; Mehta N
    Liver Transpl; 2020 May; 26(5):662-672. PubMed ID: 31833634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Median MELD at Transplant Minus 3 National Policy on Quality of Transplanted Livers for Patients With and Without Hepatocellular Carcinoma.
    Mazur RD; Cron DC; Chang DC; Yeh H; Dageforde LAD
    Transplantation; 2024 Jan; 108(1):204-214. PubMed ID: 37189232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy.
    Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA
    Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
    Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
    Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
    Shah RH; Chyou D; Goldberg DS
    Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.
    Lee E; Sarkar M; Dodge J; Kohi M; Mehta N
    Transplantation; 2020 May; 104(5):988-995. PubMed ID: 31577670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
    Saberi B; Gurakar A; Tamim H; Schneider CV; Sims OT; Bonder A; Fricker Z; Alqahtani SA
    JAMA Netw Open; 2023 Nov; 6(11):e2341096. PubMed ID: 37917059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waitlist Outcomes for Exception and Non-exception Liver Transplant Candidates in the United States Following Implementation of the Median MELD at Transplant (MMaT)/250-mile Policy.
    Ishaque T; Beckett J; Gentry S; Garonzik-Wang J; Karhadkar S; Lonze BE; Halazun KJ; Segev D; Massie AB
    Transplantation; 2024 Aug; 108(8):e170-e180. PubMed ID: 38548691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
    Alver SK; Lorenz DJ; Marvin MR; Brock GN
    Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
    Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
    Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing opportunities for liver transplant for patients with hepatocellular carcinoma.
    Zendel A; Watkins R; Moon AM; Gerber DA; Barritt AS; Desai CS
    Clin Transplant; 2022 May; 36(5):e14609. PubMed ID: 35137467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
    Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma.
    Shaikh A; Goli K; Rich NE; Benhammou JN; Khaderi S; Hernaez R; Agopian VG; Vierling JM; Kim D; Ahmed A; Goss JA; Rana A; Kanwal F; Cholankeril G
    Transplant Direct; 2022 May; 8(5):e1313. PubMed ID: 35434283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time.
    Sokolich J; Buggs J; LaVere M; Robichaux K; Rogers E; Nyce S; Kumar A; Bowers V
    Am Surg; 2020 Nov; 86(11):1592-1595. PubMed ID: 32812771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.